174 related articles for article (PubMed ID: 23074289)
1. Age-dependent associations between androgenetic alopecia and prostate cancer risk.
Muller DC; Giles GG; Sinclair R; Hopper JL; English DR; Severi G
Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):209-15. PubMed ID: 23074289
[TBL] [Abstract][Full Text] [Related]
2. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study.
Giles GG; Severi G; Sinclair R; English DR; McCredie MR; Johnson W; Boyle P; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):549-53. PubMed ID: 12050096
[TBL] [Abstract][Full Text] [Related]
3. Early onset baldness and prostate cancer risk.
Denmark-Wahnefried W; Schildkraut JM; Thompson D; Lesko SM; McIntyre L; Schwingl P; Paulson DF; Robertson CN; Anderson EE; Walther PJ
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):325-8. PubMed ID: 10750672
[TBL] [Abstract][Full Text] [Related]
4. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia.
Hayes VM; Severi G; Eggleton SA; Padilla EJ; Southey MC; Sutherland RL; Hopper JL; Giles GG
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):993-6. PubMed ID: 15824176
[TBL] [Abstract][Full Text] [Related]
5. Androgenetic alopecia as an early marker of benign prostatic hyperplasia.
Arias-Santiago S; Arrabal-Polo MA; Buendía-Eisman A; Arrabal-Martín M; Gutiérrez-Salmerón MT; Girón-Prieto MS; Jimenez-Pacheco A; Calonje JE; Naranjo-Sintes R; Zuluaga-Gomez A; Serrano Ortega S
J Am Acad Dermatol; 2012 Mar; 66(3):401-8. PubMed ID: 21835498
[TBL] [Abstract][Full Text] [Related]
6. Androgenetic alopecia at various ages and prostate cancer risk in an equal-access multiethnic case-control series of veterans.
Thomas JA; Antonelli JA; Banez LL; Hoyo C; Grant D; Demark-Wahnefried W; Platz EA; Gerber L; Shuler K; Eyoh E; Calloway E; Freedland SJ
Cancer Causes Control; 2013 May; 24(5):1045-52. PubMed ID: 23529469
[TBL] [Abstract][Full Text] [Related]
7. Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study.
Papa NP; MacInnis RJ; English DR; Bolton D; Davis ID; Lawrentschuk N; Millar JL; Severi G; Hopper JL; Giles GG
Cancer Causes Control; 2018 Jan; 29(1):93-102. PubMed ID: 29139043
[TBL] [Abstract][Full Text] [Related]
8. Association of androgenetic alopecia and hypertension.
Ahouansou S; Le Toumelin P; Crickx B; Descamps V
Eur J Dermatol; 2007; 17(3):220-2. PubMed ID: 17478384
[TBL] [Abstract][Full Text] [Related]
9. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey.
Hawk E; Breslow RA; Graubard BI
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):523-7. PubMed ID: 10815699
[TBL] [Abstract][Full Text] [Related]
10. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
Laitinen VH; Wahlfors T; Saaristo L; Rantapero T; Pelttari LM; Kilpivaara O; Laasanen SL; Kallioniemi A; Nevanlinna H; Aaltonen L; Vessella RL; Auvinen A; Visakorpi T; Tammela TL; Schleutker J
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):452-60. PubMed ID: 23292082
[TBL] [Abstract][Full Text] [Related]
11. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
12. Tea consumption and the risk of overall and grade specific prostate cancer: a large prospective cohort study of Scottish men.
Shafique K; McLoone P; Qureshi K; Leung H; Hart C; Morrison DS
Nutr Cancer; 2012 Aug; 64(6):790-7. PubMed ID: 22697604
[TBL] [Abstract][Full Text] [Related]
13. Dietary flavonoid and proanthocyanidin intakes and prostate cancer risk in a prospective cohort of US men.
Wang Y; Stevens VL; Shah R; Peterson JJ; Dwyer JT; Gapstur SM; McCullough ML
Am J Epidemiol; 2014 Apr; 179(8):974-86. PubMed ID: 24567173
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance for prostate cancer: an Australian experience.
Ischia JJ; Pang CY; Tay YK; Suen CF; Aw HC; Frydenberg M
BJU Int; 2012 Apr; 109 Suppl 3():40-3. PubMed ID: 22458492
[TBL] [Abstract][Full Text] [Related]
15. Height, body weight, and risk of prostate cancer.
Giovannucci E; Rimm EB; Stampfer MJ; Colditz GA; Willett WC
Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):557-63. PubMed ID: 9264267
[TBL] [Abstract][Full Text] [Related]
16. The risk of coronary heart disease in men with androgenetic alopecia.
Sasmaz S; Senol M; Ozcan A; Dogan G; Tuncer C; Akyol O; Sener S
J Eur Acad Dermatol Venereol; 1999 Mar; 12(2):123-5. PubMed ID: 10343940
[TBL] [Abstract][Full Text] [Related]
17. Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Zhou CK; Pfeiffer RM; Cleary SD; Hoffman HJ; Levine PH; Chu LW; Hsing AW; Cook MB
J Clin Oncol; 2015 Feb; 33(5):419-25. PubMed ID: 25225425
[TBL] [Abstract][Full Text] [Related]
18. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.
Amoretti A; Laydner H; Bergfeld W
J Am Acad Dermatol; 2013 Jun; 68(6):937-43. PubMed ID: 23395589
[TBL] [Abstract][Full Text] [Related]
19. Incidence of female androgenetic alopecia (female pattern alopecia).
Norwood OT
Dermatol Surg; 2001 Jan; 27(1):53-4. PubMed ID: 11231244
[TBL] [Abstract][Full Text] [Related]
20. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
